To study and explore the application effect of compound ipratropium bromide combined with budesonide in acute severe asthma.

100 emergency patients with severe asthma were selected as study subjects, the patients were divided into two groups by following the principles of randomized single blind, each group had 50 cases.The control group received aminophylline treatment, the observation group was treated with budesonide combined with ipratropium bromide inhalation therapy.The clinical curative effect, relieve symptoms, condition of arterial blood gas and pulmonary function were compared between the two groups.

The total effective rate of the observation group was 96%, which of the control group was 80%, the difference was statistically significant(χ²=6.061, P<0.05). The remission time of cough[(5.60±1.35)d], expectoration[(3.54±1.25)d], shortness of breath[(1.93±0.87)d], wheezing[(6.09±1.26)d] and other symptoms in the observation group were significantly shorter than those in the control group[(7.39±1.72)d, (5.17±1.54)d, (3.26±1.08)d, (8.43±1.95)d](t=5.789, 5.811, 6.781, 7.127, all P<0.05). After treatment, the arterial blood gas and lung function in the observation group were significantly improved (all P<0.05), which were better than those in the control group after treatment (all P<0.05).

The clinical curative effect of budesonide combined with ipratropium bromide in the treatment of patients with severe asthma is significant, it can improve the symptoms, pulmonary ventilation function and arterial blood gas.

Asthma; Budesonide; Compound ipratropium bromide; Emergency